^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:denifanstat (TVB-2640) (FASN inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

    Excerpt:
    ...Metastatic or advanced stage, histologically or cytologically confirmed NSCLC and molecular identification of oncogenic KRAS mutation....
    Trial ID:
    NCT03808558
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    E Clinical Medicine
    Title:

    First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

    Published date:
    03/30/2021
    Excerpt:
    Overall, 136 patients received TVB-2640...In combination with paclitaxel, the PR rate was 11% and the DCR was 70%. Responses were seen across multiple tumor types, including in patients with KRASMUT NSCLC, ovarian, and breast cancer.
    Secondary therapy:
    paclitaxel
    DOI:
    10.1016/j.eclinm.2021.100797
    Trial ID:
    NCT02223247